*p<0.001 vs placebo, multiplicity-controlled analysis ITT (NRI-C) at Weeks 2 and 16
NRI-C, non-responder imputation incorporating MI to handle missing data due to COVID-19.
EASI 75 at Week 2 was a ranked secondary endpoint. EASI 90 at week 16 was a ranked secondary endpoint. 1,3
Study design: Phase 3, randomized, placebo-controlled study of 847 adult and adolescent (≥12 years of age) patients with moderate to severe AD. Patients were randomized 1:1:1 to RINVOQ 15 mg (n=281) or 30 mg (n=285) QD monotherapy, or placebo (n=281). The co-primary endpoints (EASI 75 & vIGA-AD 0/1 at Week 16, ITT [NRI-C]) were met with both doses (p<0.001 vs placebo, multiplicity-controlled analysis).1,3
AD, Atopic dermatitis; EASI, Eczema Area and Severity Index; EASI 75, ≥75% reduction in EASI; EASI 90, ≥90% reduction in EASI; ITT, Intention-to-treat; NRI-C, Nonresponder imputation incorporating Multiple Imputation to handle missing data due to COVID-19; QD, Once daily; RCT, Randomised controlled trial; TCS, Topical corticosteroids; vIGA-AD, Validated Investigator's Global Assessment for atopic dermatitis.